Page 1 Initial REMS Approval July 2009 Most Recent Modification August 2013 NDA 21 318 FORTEO teriparatide rDNA origin Injection RISK EVALUATION AND MITIGATION STRATEGY REMS Eli Lilly and Company Indianapolis IN 46285 Telephone 317 276 2000 I Goals A Risk Mitigation To mitigate the potential risk of osteosarcoma associated with FORTEO by i alerting and warning healthcare providers and patients about the potential risk ii informing healthcare provi
NULL EForteo Pen Stylo amp Forteo FORTEO PEN Parts RA201FSCA00 teriparatide injection t riparatide injectable Pi ces du STYLO FORTEO Yellow Shaft Rubber Seal White Cap Guide de l utilisateur a Before you use your new FORTEO PEN please read the entire front and back of this User oon Manual completely Follow the directions carefully when using the FORTEO PEN Do not share your pen or needles as this may risk transmission of infectious agents U se r M a n u a